Mounjaro Geriatric (65+) Caregiver Administration Guidance

Print or save as PDFOpens the printable training log and your print dialog. No sign-up.

Can a caregiver give the Mounjaro injection at home?

Mounjaro is tirzepatide, a once-weekly subcutaneous injection approved as an adjunct to diet and exercise for type 2 diabetes in adults and children 10 and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them [1]. Mounjaro is not labeled for weight loss [1].

The Mounjaro label's administration section speaks to caregivers in plain terms. It says to tell patients and their caregivers which presentation they will receive — vial, prefilled single-dose pen, or single-patient-use KwikPen — and to make sure they receive training appropriate for that specific presentation [1]. If the prescribed presentation changes, the label says to give training for the new one and to consult the Instructions for Use for it [1]. The step-by-step technique for each presentation is in those Instructions for Use, which the label points to rather than summarizing [1].

Two limits in the same section matter for older patients. The KwikPen is not recommended for self-administration by people who are visually impaired, and it is not recommended for self-administration by pediatric patients [1]. The label also says never to share a KwikPen between patients, even if the needle is changed [1].

Injection goes into the abdomen, the thigh, or the back of the upper arm — the upper arm is injected by another person. The Mounjaro label says to rotate injection sites with each dose [1]. Doses can be given at any time of day, with or without meals [1].

Is the dose schedule different at 65 or older?

The dosing section of the Mounjaro label gives a single schedule for adults. Treatment starts at 2.5 mg once weekly, then increases in 2.5 mg increments after at least 4 weeks on the current dose if more glycemic control is needed, to a maximum of 15 mg once weekly in adults [1]. That section does not describe a separate schedule for people aged 65 and older [1]. The label says the stepwise escalation schedule is meant to reduce the risk of gastrointestinal adverse reactions [1].

Older adults were a minority of the trial population behind those numbers. In the two placebo-controlled trials pooled in the Mounjaro label, the mean age was 58 years and 4% of patients were 75 or older [1]. SURPASS-CVOT, a cardiovascular outcomes trial, randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease (mean age 64.1 years); 13,165 were included in the modified intention-to-treat analysis, and the composite of cardiovascular death, heart attack or stroke occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide (hazard ratio 0.92, 95.3% CI 0.83 to 1.01; noninferiority p=0.003; superiority p=0.09, not met) [2].

A 2024 review of drug treatment for obesity in adults 65 and older noted that concise guidelines for this age group were not available and called for trials with geriatric endpoints, including muscle mass preservation and bone quality [3].

Dehydration and kidney injury: what the label tells caregivers to watch

The label carries a warning about acute kidney injury from volume depletion. Postmarketing reports describe acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Mounjaro, and the majority of reported events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. The label directs that renal function be monitored in patients who report reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

For a caregiver, the relevant signals are the ones the label names: nausea, vomiting or diarrhea that could lead to dehydration [1]. No dose adjustment is required for renal or hepatic impairment [1].

Common gastrointestinal side effects, by dose

In the pooled placebo-controlled trials in adults with type 2 diabetes — mean age 58 — the label reports nausea in 4% of placebo patients versus 12% at 5 mg, 15% at 10 mg and 18% at 15 mg; diarrhea in 9% versus 12%, 13% and 17%; vomiting in 2% versus 5%, 5% and 9%; and constipation in 1% versus 6%, 6% and 7% [1]. Decreased appetite ran 1% versus 5%, 10% and 11% [1]. Most reports of nausea, vomiting or diarrhea occurred during dose escalation and decreased over time [1].

Severe gastrointestinal adverse reactions were reported in 1.3% of patients on 5 mg, 0.4% on 10 mg and 1.2% on 15 mg, versus 0.9% on placebo [1]. Mounjaro is not recommended in patients with severe gastroparesis [1].

Hypoglycemia when the patient also takes insulin or a sulfonylurea

The label warns that patients receiving Mounjaro with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia, and that the risk may be lowered by reducing the dose of the sulfonylurea or insulin [1]. When Mounjaro is started, the label says to consider reducing the dose of a concomitant insulin secretagogue or insulin [1]. It also directs that people using these combinations be told about the risk and taught the signs and symptoms of hypoglycemia [1].

Muscle mass during weight loss

Tirzepatide lowers body weight with greater fat mass loss than lean mass loss, in the label's wording [1]. The clearest numbers come from a body-composition substudy of SURMOUNT-1, a trial in adults with obesity or overweight without diabetes [4]. Of 160 participants with scans at baseline and week 72, 124 received pooled tirzepatide doses and 36 received placebo; body weight changed by -21.3% versus -5.3%, fat mass by -33.9% versus -8.2%, and lean mass by -10.9% versus -2.6% [4]. About 75% of the weight lost was fat mass and about 25% lean mass on both tirzepatide and placebo [4]. Post hoc analyses by age group (including 65 and older), sex and weight-loss tertile were consistent across most subgroups, but the substudy was small and the scan method does not separate muscle from other lean tissue [4].

Missed doses and changing the injection day

If a dose is missed, the label says to give it as soon as possible within 4 days (96 hours) of the missed dose; if more than 4 days have passed, skip it and give the next dose on the regularly scheduled day [1]. The weekly day can be changed as long as the gap between two doses is at least 3 days (72 hours) [1].

Other label warnings a caregiver should know

• Pancreatitis. The label says to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and to discontinue Mounjaro if pancreatitis is suspected [1].
• Serious allergy. Anaphylaxis and angioedema have been reported; the label says to discontinue Mounjaro if a hypersensitivity reaction is suspected, treat promptly, and seek medical advice [1]. A personal or family history of medullary thyroid carcinoma or MEN 2, or a known serious hypersensitivity to tirzepatide or an excipient, are contraindications [1].
• Thyroid C-cell tumors (boxed warning). Tirzepatide caused dose- and duration-dependent thyroid C-cell tumors in rats at clinically relevant exposures; human relevance is unknown [1]. Patients are to be counseled on symptoms of thyroid tumors — a neck mass, difficulty swallowing, shortness of breath, persistent hoarseness — and routine calcitonin testing or thyroid ultrasound is of uncertain value [1].
• Gallbladder disease. Acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo patients in adult placebo-controlled trials [1].
• Diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression [1].
• Procedures. Pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists during general anesthesia or deep sedation, and the label says to instruct patients to tell their healthcare providers about any planned surgery or procedure [1].